Overview
Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.
Current Appointments & Affiliations
James B. Duke Distinguished Professor of Biostatistics & Bioinformatics
·
2023 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Professor of Biostatistics & Bioinformatics
·
2012 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Chief, Division of Biostatistics
·
2019 - Present
Biostatistics & Bioinformatics,
Basic Science Departments
Member of the Duke Cancer Institute
·
1996 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601.
Journal Article JCO Precis Oncol · July 2025 PURPOSE: In urothelial carcinoma, prior studies have indicated that the basal/squamous molecular subtype and the presence of select DNA damage response (DDR) gene alterations are associated with improved benefit from cisplatin-based chemotherapy. We sought ... Full text Link to item CiteHow To Interpret Subgroup Analyses from Prospective Randomized Clinical Trials: What Clinicians Need To Know.
Journal Article Eur Urol · July 1, 2025 Subgroup analyses must be approached with caution. Only prespecified, well-powered analyses with formal interaction testing and validation can support strong claims; exploratory findings require confirmation. Integration of statistical rigor with clinical ... Full text Link to item CitePrognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.
Journal Article Prostate Cancer Prostatic Dis · June 2025 BACKGROUND: CALGB 90401 (Alliance) was a phase III trial of 1050 patients with metastatic castration-resistant prostate cancer (mCRPC) comparing docetaxel, prednisone, bevacizumab (DP+B) versus DP alone. While this trial did not show an improvement in over ... Full text Link to item CiteRecent Grants
Research Triangle Center of Excellence in Regulatory Science and Innovation
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028DoD: PCRP Clinical Consortium: Duke University Clinical Research Site
ResearchCo Investigator · Awarded by Department of Defense · 2007 - 2026Understanding heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era
ResearchPrincipal Investigator · Awarded by Department of Defense · 2023 - 2026View All Grants
Education, Training & Certifications
University of Texas Health Sciences Center, Houston ·
1994
Ph.D.